[What's new in internal medicine?].
Among diagnostic progress over the last three years in internal medicine, Antisynthetase Syndrome is now more easily recognised with the diffusion of laboratory tests for research of antibodies against tRNA synthetases (Anti JO1, anti PL7, Anti PL12). In two third of cases, these antibodies are found despite absence of antinuclear antibodies. Hence, we have to search them specifically in patients with polyarthritis associated with myositis, cutaneous manifestations (Raynaud phenomenom and "mechanic'hands") and interstitial lung disease. Discovery of asymptomatic mutation in the L ferritin coding sequence help us to better understand the "unexplained" hyperferritinemia. Initially described by japonese gastroenterologists, auto immune pancreatitis in fact a part of a systemic sclerosing disease with a biochemical hallmark: in crease of a subclass of immunoglobulins G (IgG4). A new pediatric disease due to a deficiency of the interleukin1 receptor antagonist (multifocal aseptic osteitis, periostitis, stomatitis, disseminated pustulosis) help us to better understand unexplained auto inflammatory diseases. The therapeutic progress is primarily due to an explosion of biological therapies, particularly four of them very useful for internists (in an off label use) : Interleukin 1 inhibitors (anakinra, Canakinumab) to treat some auto inflammatory diseases (cryopirin associated periodic syndromes and deficency of interleukin 1 receptor antagonist), monoclonal antibody against interleukin 5 (mepolizumab) to treat some hypereosinophilic syndromes and Churg and Strauss angiitis, interleukin 6 inhibitiors to treat multifocal Castleman's disease and adult Still disease, a monoclonal antibody against vascular endothelial growth factor (Bevacizumab) to treat hereditary hemorrhagic telangiectasia.
Blétry
O
O
Service de Médecine Interne, Hôpital Foch, Suresnes, France. o.bletry@hopital-foch.org
Sene
T
T
Kahn
J-E
JE
Ackermann
F
F
Charles
P
P
Leport
J
J
Piette
A-M
AM
D056150:Acute Generalized Exanthematous Pustulosis / Q000175:diagnosis / Q000276:immunology; D000604:Amino Acyl-tRNA Synthetases / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001168:Arthritis / Q000175:diagnosis / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D015415:Biomarkers / Q000378:metabolism; D004359:Drug Therapy, Combination; D005293:Ferritins / Q000235:genetics; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D007388:Internal Medicine / Q000639:trends*; D019190:Iron Overload / Q000175:diagnosis / Q000235:genetics; D017563:Lung Diseases, Interstitial / Q000175:diagnosis / Q000276:immunology; D009154:Mutation; D009220:Myositis / Q000175:diagnosis / Q000276:immunology; D010000:Osteitis / Q000175:diagnosis / Q000276:immunology; D010195:Pancreatitis / Q000175:diagnosis / Q000276:immunology; D010522:Periostitis / Q000175:diagnosis / Q000276:immunology; D011928:Raynaud Disease / Q000175:diagnosis / Q000276:immunology; D013280:Stomatitis / Q000175:diagnosis / Q000276:immunology; D013577:Syndrome; D016896:Treatment Outcome; D000093242:Interleukin-6 Inhibitors
D000604:Amino Acyl-tRNA Synthetases; D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D015415:Biomarkers; D005293:Ferritins; D053590:Interleukin 1 Receptor Antagonist Protein; D000093242:Interleukin-6 Inhibitors